NEJM — Recent Cardiology Articles- Survodutide Once Weekly for the Treatment of Adults with Obesity June 7, 2026In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo.
- Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology June 6, 2026Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing.
- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026How did a drug for congestive heart failure get approved and marketed for Black people only?
- Left Atrial Appendage Closure — Should Recommendations Be Expanded? June 4, 2026Owing to the fact that most thromboembolic complications that are attributed to atrial fibrillation originate in the left atrial appendage,1 therapies targeting the anatomical structure that might spare systemic harms are theoretically attractive. Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart...
- Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation June 4, 2026In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding.
- Survodutide Once Weekly for the Treatment of Adults with Obesity June 7, 2026
